Definitive Contract 75A50123C00062
Award Date
9/25/23
Potential Completion Date
7/2/26
Potential Value
$433M
Awardee
Gritstone Bio, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Boston, MA 02215, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...
This $135,212,671.14 federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Gigagen Inc., a for-profit foreign-owned company, for the development of a next-generation recombinant polyclonal antibody discovery platform to produce medical countermeasures. The contract was awarded under BARDA's (Biomedical Advanced Research and Development Authority) Broad Agency...
This is a $26,261,466 cost-plus-fixed-fee contract awarded by the Defense Threat Reduction Agency (DTRA) to the International AIDS Vaccine Initiative (IAVI) to accelerate development of a SARS-CoV-2 vaccine based on the live VSV∆G chimeric virus platform. The contract has no set-aside designation. IAVI is working with several subcontractors, including Trustees of Boston University, Merck Sharp & Dohme LLC, Neogenomics Laboratories, Charles River Laboratories Montreal ULC, and the...
This is a $37,000 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Protein Sciences Corp, a for-profit manufacturer, to provide purified recombinant proteins. The contract has no set-aside designation. Protein Sciences Corp has received multiple federal contract awards from HHS's Office of the Assistant Secretary for Preparedness and Response...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company, to provide protein antigen production for coronavirus vaccine antigens in support of COVID-19 research. The $139,989.48 contract has a completion date of September 23, 2022. Genscript has previously received federal awards from agencies such as the USDA to...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $12,996,780.00 prime contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Battelle Memorial Institute. The contract supports the development of assays and reagents for coronavirus vaccines. It was issued as a cost-plus-fixed-fee delivery order under a larger NIAID contract, with no set-aside designation. Key subcontractors include Beckman Coulter, Inc., Meso Scale Diagnostics LLC, Fisher...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This is a delivery order contract award by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Battelle Memorial Institute, a nonprofit research and development organization, for immunogenicity and efficacy testing of medical countermeasures (vaccines and other biologics) against emerging infectious diseases including COVID-19 (SARS-CoV-2). The total ceiling value of the contract is $12,290,377.00. The contract is...
This is a $125,647,983.00 definitive contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the advanced development and manufacturing of a COVID-19 vaccine. It was awarded under a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA) that sought...